Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Meta-Analysis

Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis

Author(s): Baomin Zheng, Meilin He, Yaqian Han, Xin Jiang, Xiaomin Ou, Peng Zhang, Ruyuan Guo, Jingao Li, Ximei Zhang, Qiao Qiao, Hui Wu, Man Hu, Mei Feng, Wenyong Tu and Junlin Yi*

Volume 24, Issue 9, 2024

Published on: 15 February, 2024

Page: [952 - 966] Pages: 15

DOI: 10.2174/0115680096281982240117114819

Price: $65

Open Access Journals Promotions 2
Abstract

Background: The present meta-analysis aimed to evaluate the efficacy and safety of adding nimotuzumab to radiotherapy (RT) or chemoradiotherapy (CRT).

Methods: Prospective randomized controlled studies at EMBASE, PubMed, and the Cochrane Library from January 1, 2010, to October 1, 2022, were searched. Data on the overall survival (OS), progress-free survival (PFS), disease-free survival (DFS), complete response rate (CRR), objective response rate (ORR), and all grade adverse events were collected from the enrolled publications. OS was the primary measurement indicator. Pooled analysis was performed with relative risks (RRs), hazard risks (HRs), and their corresponding 95% confidence intervals (CIs) in the software Stata SE 16.0.

Results: Six randomized controlled studies were included in the analysis of the overall pooled effect. As compared to the control group, the nimotuzumab intervention group exhibited improved OS by 21% (pooled HR=0.79,95% CI: 0.64-0.98, P=0.028), along with PFS up to 31% (HR=0.69, 95% CI: 0.55-0.86, P=0.001) and DFS up to 29% (HR=0.71, 95% CI: 0.56-0.91, P=0.006), increased CRR as 50% (RR=1.50, 95% CI:1.09-2.04; P=0.012), and ORR as 35% (RR=1.35, 95% CI:1.04-1.73; P=0.022). Regarding safety, nimotuzumab in combination with RT or CRT did not increase the incidence of all grade adverse events (pooled-RD=-1.27, 95% CI:-2.78-0.23, P=0.099).

Conclusion: The present meta-analysis has demonstrated that nimotuzumab, in combination with RT or CRT, could provide survival benefits and increase response rates. Its safety profile has been found to be controllable.

Keywords: Nimotuzumab, radiotherapy, chemoradiotherapy, head and neck cancer, nasopharynx, targeted therapy.

[1]
Fitzmaurice, C.; Abate, D.; Abbasi, N.; Abbastabar, H.; Abd-Allah, F.; Abdel-Rahman, O.; Abdelalim, A.; Abdoli, A.; Abdollahpour, I.; Abdulle, A.S.M.; Abebe, N.D.; Abraha, H.N.; Abu-Raddad, L.J.; Abualhasan, A.; Adedeji, I.A.; Advani, S.M.; Afarideh, M.; Afshari, M.; Aghaali, M.; Agius, D.; Agrawal, S.; Ahmadi, A.; Ahmadian, E.; Ahmadpour, E.; Ahmed, M.B.; Akbari, M.E.; Akinyemiju, T.; Al-Aly, Z.; AlAbdulKader, A.M.; Alahdab, F.; Alam, T.; Alamene, G.M.; Alemnew, B.T.T.; Alene, K.A.; Alinia, C.; Alipour, V.; Aljunid, S.M.; Bakeshei, F.A.; Almadi, M.A.H.; Almasi-Hashiani, A.; Alsharif, U.; Alsowaidi, S.; Alvis-Guzman, N.; Amini, E.; Amini, S.; Amoako, Y.A.; Anbari, Z.; Anber, N.H.; Andrei, C.L.; Anjomshoa, M.; Ansari, F.; Ansariadi, A.; Appiah, S.C.Y.; Arab-Zozani, M.; Arabloo, J.; Arefi, Z.; Aremu, O.; Areri, H.A.; Artaman, A.; Asayesh, H.; Asfaw, E.T.; Ashagre, A.F.; Assadi, R.; Ataeinia, B.; Atalay, H.T.; Ataro, Z.; Atique, S.; Ausloos, M.; Avila-Burgos, L.; Avokpaho, E.F.G.A.; Awasthi, A.; Awoke, N.; Ayala Quintanilla, B.P.; Ayanore, M.A.; Ayele, H.T.; Babaee, E.; Bacha, U.; Badawi, A.; Bagherzadeh, M.; Bagli, E.; Balakrishnan, S.; Balouchi, A.; Bärnighausen, T.W.; Battista, R.J.; Behzadifar, M.; Behzadifar, M.; Bekele, B.B.; Belay, Y.B.; Belayneh, Y.M.; Berfield, K.K.S.; Berhane, A.; Bernabe, E.; Beuran, M.; Bhakta, N.; Bhattacharyya, K.; Biadgo, B.; Bijani, A.; Bin Sayeed, M.S.; Birungi, C.; Bisignano, C.; Bitew, H.; Bjørge, T.; Bleyer, A.; Bogale, K.A.; Bojia, H.A.; Borzì, A.M.; Bosetti, C.; Bou-Orm, I.R.; Brenner, H.; Brewer, J.D.; Briko, A.N.; Briko, N.I.; Bustamante-Teixeira, M.T.; Butt, Z.A.; Carreras, G.; Carrero, J.J.; Carvalho, F.; Castro, C.; Castro, F.; Catalá-López, F.; Cerin, E.; Chaiah, Y.; Chanie, W.F.; Chattu, V.K.; Chaturvedi, P.; Chauhan, N.S.; Chehrazi, M.; Chiang, P.P.C.; Chichiabellu, T.Y.; Chido-Amajuoyi, O.G.; Chimed-Ochir, O.; Choi, J.Y.J.; Christopher, D.J.; Chu, D.T.; Constantin, M.M.; Costa, V.M.; Crocetti, E.; Crowe, C.S.; Curado, M.P.; Dahlawi, S.M.A.; Damiani, G.; Darwish, A.H.; Daryani, A.; das Neves, J.; Demeke, F.M.; Demis, A.B.; Demissie, B.W.; Demoz, G.T.; Denova-Gutiérrez, E.; Derakhshani, A.; Deribe, K.S.; Desai, R.; Desalegn, B.B.; Desta, M.; Dey, S.; Dharmaratne, S.D.; Dhimal, M.; Diaz, D.; Dinberu, M.T.T.; Djalalinia, S.; Doku, D.T.; Drake, T.M.; Dubey, M.; Dubljanin, E.; Duken, E.E.; Ebrahimi, H.; Effiong, A.; Eftekhari, A.; El Sayed, I.; Zaki, M.E.S.; El-Jaafary, S.I.; El-Khatib, Z.; Elemineh, D.A.; Elkout, H.; Ellenbogen, R.G.; Elsharkawy, A.; Emamian, M.H.; Endalew, D.A.; Endries, A.Y.; Eshrati, B.; Fadhil, I.; Fallah Omrani, V.; Faramarzi, M.; Farhangi, M.A.; Farioli, A.; Farzadfar, F.; Fentahun, N.; Fernandes, E.; Feyissa, G.T.; Filip, I.; Fischer, F.; Fisher, J.L.; Force, L.M.; Foroutan, M.; Freitas, M.; Fukumoto, T.; Futran, N.D.; Gallus, S.; Gankpe, F.G.; Gayesa, R.T.; Gebrehiwot, T.T.; Gebremeskel, G.G.; Gedefaw, G.A.; Gelaw, B.K.; Geta, B.; Getachew, S.; Gezae, K.E.; Ghafourifard, M.; Ghajar, A.; Ghashghaee, A.; Gholamian, A.; Gill, P.S.; Ginindza, T.T.G.; Girmay, A.; Gizaw, M.; Gomez, R.S.; Gopalani, S.V.; Gorini, G.; Goulart, B.N.G.; Grada, A.; Ribeiro Guerra, M.; Guimaraes, A.L.S.; Gupta, P.C.; Gupta, R.; Hadkhale, K.; Haj-Mirzaian, A.; Haj-Mirzaian, A.; Hamadeh, R.R.; Hamidi, S.; Hanfore, L.K.; Haro, J.M.; Hasankhani, M.; Hasanzadeh, A.; Hassen, H.Y.; Hay, R.J.; Hay, S.I.; Henok, A.; Henry, N.J.; Herteliu, C.; Hidru, H.D.; Hoang, C.L.; Hole, M.K.; Hoogar, P.; Horita, N.; Hosgood, H.D.; Hosseini, M.; Hosseinzadeh, M.; Hostiuc, M.; Hostiuc, S.; Househ, M.; Hussen, M.M.; Ileanu, B.; Ilic, M.D.; Innos, K.; Irvani, S.S.N.; Iseh, K.R.; Islam, S.M.S.; Islami, F.; Jafari Balalami, N.; Jafarinia, M.; Jahangiry, L.; Jahani, M.A.; Jahanmehr, N.; Jakovljevic, M.; James, S.L.; Javanbakht, M.; Jayaraman, S.; Jee, S.H.; Jenabi, E.; Jha, R.P.; Jonas, J.B.; Jonnagaddala, J.; Joo, T.; Jungari, S.B.; Jürisson, M.; Kabir, A.; Kamangar, F.; Karch, A.; Karimi, N.; Karimian, A.; Kasaeian, A.; Kasahun, G.G.; Kassa, B.; Kassa, T.D.; Kassaw, M.W.; Kaul, A.; Keiyoro, P.N.; Kelbore, A.G.; Kerbo, A.A.; Khader, Y.S.; Khalilarjmandi, M.; Khan, E.A.; Khan, G.; Khang, Y.H.; Khatab, K.; Khater, A.; Khayamzadeh, M.; Khazaee-Pool, M.; Khazaei, S.; Khoja, A.T.; Khosravi, M.H.; Khubchandani, J.; Kianipour, N.; Kim, D.; Kim, Y.J.; Kisa, A.; Kisa, S.; Kissimova-Skarbek, K.; Komaki, H.; Koyanagi, A.; Krohn, K.J.; Bicer, B.K.; Kugbey, N.; Kumar, V.; Kuupiel, D.; La Vecchia, C.; Lad, D.P.; Lake, E.A.; Lakew, A.M.; Lal, D.K.; Lami, F.H.; Lan, Q.; Lasrado, S.; Lauriola, P.; Lazarus, J.V.; Leigh, J.; Leshargie, C.T.; Liao, Y.; Limenih, M.A.; Listl, S.; Lopez, A.D.; Lopukhov, P.D.; Lunevicius, R.; Madadin, M.; Magdeldin, S.; El Razek, H.M.A.; Majeed, A.; Maleki, A.; Malekzadeh, R.; Manafi, A.; Manafi, N.; Manamo, W.A.; Mansourian, M.; Mansournia, M.A.; Mantovani, L.G.; Maroufizadeh, S.; Martini, S.M.S.; Mashamba-Thompson, T.P.; Massenburg, B.B.; Maswabi, M.T.; Mathur, M.R.; McAlinden, C.; McKee, M.; Meheretu, H.A.A.; Mehrotra, R.; Mehta, V.; Meier, T.; Melaku, Y.A.; Meles, G.G.; Meles, H.G.; Melese, A.; Melku, M.; Memiah, P.T.N.; Mendoza, W.; Menezes, R.G.; Merat, S.; Meretoja, T.J.; Mestrovic, T.; Miazgowski, B.; Miazgowski, T.; Mihretie, K.M.M.; Miller, T.R.; Mills, E.J.; Mir, S.M.; Mirzaei, H.; Mirzaei, H.R.; Mishra, R.; Moazen, B.; Mohammad, D.K.; Mohammad, K.A.; Mohammad, Y.; Darwesh, A.M.; Mohammadbeigi, A.; Mohammadi, H.; Mohammadi, M.; Mohammadian, M.; Mohammadian-Hafshejani, A.; Mohammadoo-Khorasani, M.; Mohammadpourhodki, R.; Mohammed, A.S.; Mohammed, J.A.; Mohammed, S.; Mohebi, F.; Mokdad, A.H.; Monasta, L.; Moodley, Y.; Moosazadeh, M.; Moossavi, M.; Moradi, G.; Moradi-Joo, M.; Moradi-Lakeh, M.; Moradpour, F.; Morawska, L.; Morgado-da-Costa, J.; Morisaki, N.; Morrison, S.D.; Mosapour, A.; Mousavi, S.M.; Muche, A.A.; Muhammed, O.S.S.; Musa, J.; Nabhan, A.F.; Naderi, M.; Nagarajan, A.J.; Nagel, G.; Nahvijou, A.; Naik, G.; Najafi, F.; Naldi, L.; Nam, H.S.; Nasiri, N.; Nazari, J.; Negoi, I.; Neupane, S.; Newcomb, P.A.; Nggada, H.A.; Ngunjiri, J.W.; Nguyen, C.T.; Nikniaz, L.; Ningrum, D.N.A.; Nirayo, Y.L.; Nixon, M.R.; Nnaji, C.A.; Nojomi, M.; Nosratnejad, S.; Shiadeh, M.N.; Obsa, M.S.; Ofori-Asenso, R.; Ogbo, F.A.; Oh, I.H.; Olagunju, A.T.; Olagunju, T.O.; Oluwasanu, M.M.; Omonisi, A.E.; Onwujekwe, O.E.; Oommen, A.M.; Oren, E.; Ortega-Altamirano, D.D.V.; Ota, E.; Otstavnov, S.S.; Owolabi, M.O.; P A, M.; Padubidri, J.R.; Pakhale, S.; Pakpour, A.H.; Pana, A.; Park, E.K.; Parsian, H.; Pashaei, T.; Patel, S.; Patil, S.T.; Pennini, A.; Pereira, D.M.; Piccinelli, C.; Pillay, J.D.; Pirestani, M.; Pishgar, F.; Postma, M.J.; Pourjafar, H.; Pourmalek, F.; Pourshams, A.; Prakash, S.; Prasad, N.; Qorbani, M.; Rabiee, M.; Rabiee, N.; Radfar, A.; Rafiei, A.; Rahim, F.; Rahimi, M.; Rahman, M.A.; Rajati, F.; Rana, S.M.; Raoofi, S.; Rath, G.K.; Rawaf, D.L.; Rawaf, S.; Reiner, R.C.; Renzaho, A.M.N.; Rezaei, N.; Rezapour, A.; Ribeiro, A.I.; Ribeiro, D.; Ronfani, L.; Roro, E.M.; Roshandel, G.; Rostami, A.; Saad, R.S.; Sabbagh, P.; Sabour, S.; Saddik, B.; Safiri, S.; Sahebkar, A.; Salahshoor, M.R.; Salehi, F.; Salem, H.; Salem, M.R.; Salimzadeh, H.; Salomon, J.A.; Samy, A.M.; Sanabria, J.; Santric Milicevic, M.M.; Sartorius, B.; Sarveazad, A.; Sathian, B.; Satpathy, M.; Savic, M.; Sawhney, M.; Sayyah, M.; Schneider, I.J.C.; Schöttker, B.; Sekerija, M.; Sepanlou, S.G.; Sepehrimanesh, M.; Seyedmousavi, S.; Shaahmadi, F.; Shabaninejad, H.; Shahbaz, M.; Shaikh, M.A.; Shamshirian, A.; Shamsizadeh, M.; Sharafi, H.; Sharafi, Z.; Sharif, M.; Sharifi, A.; Sharifi, H.; Sharma, R.; Sheikh, A.; Shirkoohi, R.; Shukla, S.R.; Si, S.; Siabani, S.; Silva, D.A.S.; Silveira, D.G.A.; Singh, A.; Singh, J.A.; Sisay, S.; Sitas, F.; Sobngwi, E.; Soofi, M.; Soriano, J.B.; Stathopoulou, V.; Sufiyan, M.B.; Tabarés-Seisdedos, R.; Tabuchi, T.; Takahashi, K.; Tamtaji, O.R.; Tarawneh, M.R.; Tassew, S.G.; Taymoori, P.; Tehrani-Banihashemi, A.; Temsah, M.H.; Temsah, O.; Tesfay, B.E.; Tesfay, F.H.; Teshale, M.Y.; Tessema, G.A.; Thapa, S.; Tlaye, K.G.; Topor-Madry, R.; Tovani-Palone, M.R.; Traini, E.; Tran, B.X.; Tran, K.B.; Tsadik, A.G.; Ullah, I.; Uthman, O.A.; Vacante, M.; Vaezi, M.; Varona Pérez, P.; Veisani, Y.; Vidale, S.; Violante, F.S.; Vlassov, V.; Vollset, S.E.; Vos, T.; Vosoughi, K.; Vu, G.T.; Vujcic, I.S.; Wabinga, H.; Wachamo, T.M.; Wagnew, F.S.; Waheed, Y.; Weldegebreal, F.; Weldesamuel, G.T.; Wijeratne, T.; Wondafrash, D.Z.; Wonde, T.E.; Wondmieneh, A.B.; Workie, H.M.; Yadav, R.; Yadegar, A.; Yadollahpour, A.; Yaseri, M.; Yazdi-Feyzabadi, V.; Yeshaneh, A.; Yimam, M.A.; Yimer, E.M.; Yisma, E.; Yonemoto, N.; Younis, M.Z.; Yousefi, B.; Yousefifard, M.; Yu, C.; Zabeh, E.; Zadnik, V.; Moghadam, T.Z.; Zaidi, Z.; Zamani, M.; Zandian, H.; Zangeneh, A.; Zaki, L.; Zendehdel, K.; Zenebe, Z.M.; Zewale, T.A.; Ziapour, A.; Zodpey, S.; Murray, C.J.L. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017. JAMA Oncol., 2019, 5(12), 1749-1768.
[http://dx.doi.org/10.1001/jamaoncol.2019.2996] [PMID: 31560378]
[2]
Aupérin, A. Epidemiology of head and neck cancers: An update. Curr. Opin. Oncol., 2020, 32(3), 178-186.
[http://dx.doi.org/10.1097/CCO.0000000000000629] [PMID: 32209823]
[3]
Wang, X.; Hu, C. Application of anti-EGFR monoclonal antibody targeted drugs in the comprehensive treatment of head and neck squamous cell carcinoma. Chin. J. Cancer, 2018, 28(12), 7. [J].
[4]
Pfister, D.G.; Spencer, S.; Adelstein, D.; Adkins, D.; Anzai, Y.; Brizel, D.M.; Bruce, J.Y.; Busse, P.M.; Caudell, J.J.; Cmelak, A.J.; Colevas, A.D.; Eisele, D.W.; Fenton, M.; Foote, R.L.; Galloway, T.; Gillison, M.L.; Haddad, R.I.; Hicks, W.L.; Hitchcock, Y.J.; Jimeno, A.; Leizman, D.; Maghami, E.; Mell, L.K.; Mittal, B.B.; Pinto, H.A.; Ridge, J.A.; Rocco, J.W.; Rodriguez, C.P.; Shah, J.P.; Weber, R.S.; Weinstein, G.; Witek, M.; Worden, F.; Yom, S.S.; Zhen, W.; Burns, J.L.; Darlow, S.D. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw., 2020, 18(7), 873-898.
[http://dx.doi.org/10.6004/jnccn.2020.0031] [PMID: 32634781]
[5]
Grandis, J.R.; Melhem, M.F.; Gooding, W.E.; Day, R.; Holst, V.A.; Wagener, M.M.; Drenning, S.D.; Tweardy, D.J. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst., 1998, 90(11), 824-832.
[http://dx.doi.org/10.1093/jnci/90.11.824] [PMID: 9625170]
[6]
Zhu, X.; Zhang, F.; Zhang, W.; He, J.; Zhao, Y.; Chen, X. Prognostic role of epidermal growth factor receptor in head and neck cancer: A meta-analysis. J. Surg. Oncol., 2013, 108(6), 387-397.
[http://dx.doi.org/10.1002/jso.23406] [PMID: 24038070]
[7]
Ang, K.K.; Zhang, Q.; Rosenthal, D.I.; Nguyen-Tan, P.F.; Sherman, E.J.; Weber, R.S.; Galvin, J.M.; Bonner, J.A.; Harris, J.; El-Naggar, A.K.; Gillison, M.L.; Jordan, R.C.; Konski, A.A.; Thorstad, W.L.; Trotti, A.; Beitler, J.J.; Garden, A.S.; Spanos, W.J.; Yom, S.S.; Axelrod, R.S. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J. Clin. Oncol., 2014, 32(27), 2940-2950.
[http://dx.doi.org/10.1200/JCO.2013.53.5633] [PMID: 25154822]
[8]
Mesía, R.; Henke, M.; Fortin, A.; Minn, H.; Yunes Ancona, A.C.; Cmelak, A.; Markowitz, A.B.; Hotte, S.J.; Singh, S.; Chan, A.T.C.; Merlano, M.C.; Skladowski, K.; Zhang, A.; Oliner, K.S.; VanderWalde, A.; Giralt, J. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): A randomised, controlled, open-label phase 2 trial. Lancet Oncol., 2015, 16(2), 208-220.
[http://dx.doi.org/10.1016/S1470-2045(14)71198-2] [PMID: 25596660]
[9]
Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M.S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E.K.; Ang, K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 2006, 354(6), 567-578.
[http://dx.doi.org/10.1056/NEJMoa053422] [PMID: 16467544]
[10]
Giralt, J.; Trigo, J.; Nuyts, S.; Ozsahin, M.; Skladowski, K.; Hatoum, G.; Daisne, J.F.; Yunes Ancona, A.C.; Cmelak, A.; Mesía, R.; Zhang, A.; Oliner, K.S.; VanderWalde, A. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): A randomised, controlled, open-label phase 2 trial. Lancet Oncol., 2015, 16(2), 221-232.
[http://dx.doi.org/10.1016/S1470-2045(14)71200-8] [PMID: 25596659]
[11]
Tian, Y.; Lin, J.; Tian, Y.; Zhang, G.; Zeng, X.; Zheng, R.; Zhang, W.; Yuan, Y. Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized controlled trials. Int. J. Cancer, 2018, 142(11), 2198-2206.
[http://dx.doi.org/10.1002/ijc.31157] [PMID: 29143328]
[12]
Song, Q; Li, X; Li, B; Di, B; Xiao, S. Anti-EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: A meta-analysis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2015, 29(9), 815-821.
[13]
Mao, L.; Tan, J.; Wang, F.; Luo, Y.; Liu, W.; Zeng, F.; Yu, B.; Huang, H.; Lu, J.; Peng, X.; Liu, X. Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression. Clin. Otolaryngol., 2019, 44(4), 572-580.
[http://dx.doi.org/10.1111/coa.13340] [PMID: 30972891]
[14]
You, R.; Hua, Y.J.; Liu, Y.P.; Yang, Q.; Zhang, Y.N.; Li, J.B.; Li, C.F.; Zou, X.; Yu, T.; Cao, J.Y.; Zhang, M.X.; Jiang, R.; Sun, R.; Mo, H.Y.; Guo, L.; Cao, K.J.; Lin, A.H.; Sun, Y.; Qian, C.N.; Ma, J.; Chen, M.Y. Concurrent chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: Retrospective analysis with a large cohort and long follow-up. Theranostics, 2017, 7(8), 2314-2324.
[http://dx.doi.org/10.7150/thno.19710] [PMID: 28740554]
[15]
Liu, Z.; Zhao, Y.; Tang, J.; Zhou, Y.; Yang, W.; Qiu, Y.; Wang, H. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective analysis. Oncotarget, 2016, 7(17), 24429-24435.
[http://dx.doi.org/10.18632/oncotarget.8225] [PMID: 27016412]
[16]
Peng, L.; Liu, Z.L.; Xu, C.; Tang, L.L.; Liu, X.; Lin, A.H.; Sun, Y.; Chen, Y.P.; Ma, J. The efficacy and safety of anti-epidermal growth factor receptor monoclonal antibodies in nasopharyngeal carcinoma: Literature-based meta-analyses. J. Cancer, 2018, 9(23), 4510-4520.
[http://dx.doi.org/10.7150/jca.27611] [PMID: 30519357]
[17]
Yao, J.J.; Zhang, L.L.; Gao, T.S.; Peng, Y.L.; Lawrence, W.R.; Zhang, W.J.; Zhang, F.; Zhou, G.Q.; Wang, S.Y.; Sun, Y. Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Biol. Ther., 2018, 19(12), 1102-1107.
[http://dx.doi.org/10.1080/15384047.2018.1491501] [PMID: 30081714]
[18]
Fei, Z.; Xu, T.; Li, M.; Chen, T.; Li, L.; Qiu, X.; Chen, C. Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma. Radiat. Oncol., 2020, 15(1), 230.
[http://dx.doi.org/10.1186/s13014-020-01674-5] [PMID: 33008416]
[19]
Rawat, S.; Tandan, H.; Patel, S.; Chaudhari, S. Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural hospital experience. South Asian J. Cancer, 2019, 8(1), 52-56.
[http://dx.doi.org/10.4103/sajc.sajc_76_18] [PMID: 30766856]
[20]
Liang, Z.G.; Lin, G.X.; Ye, J.X.; Li, Y.; Li, L.; Qu, S.; Liang, X.; Zhu, X.D. Cetuximab or nimotuzumab versus cisplatin concurrent with radiotherapy for local-regionally advanced nasopharyngeal carcinoma: A meta-analysis. Asian Pac. J. Cancer Prev., 2018, 19(5), 1397-1404.
[PMID: 29802706]
[21]
Ang, M.K.; Montoya, J.E.; Tharavichitkul, E.; Lim, C.; Tan, T.; Wang, L.Y.; Wee, J.; Soong, Y.L.; Fong, K.W.; Ng, Q.S.; Tan, D.S.W.; Toh, C.K.; Tan, E.H.; Lim, W.T. Phase II study of nimotuzumab ( THERACIM-HR3 ) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. Head Neck, 2021, 43(5), 1641-1651.
[http://dx.doi.org/10.1002/hed.26635] [PMID: 33547683]
[22]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ, 2009, 339(jul21 1), b2535.
[http://dx.doi.org/10.1136/bmj.b2535] [PMID: 19622551]
[23]
Higgins, JPT; Green, S Cochrane handbook for systematic reviews of interventions 5.1.0. 2011. Cochrane training., 2017.
[24]
Guyot, P.; Ades, A.E.; Ouwens, M.J.N.M.; Welton, N.J. Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol., 2012, 12(1), 9.
[http://dx.doi.org/10.1186/1471-2288-12-9] [PMID: 22297116]
[25]
Reddy, B.K.M.; Lokesh, V.; Vidyasagar, M.S.; Shenoy, K.; Babu, K.G.; Shenoy, A.; Naveen, T.; Joseph, B.; Bonanthaya, R.; Nanjundappa; Bapsy, P.P.; Loknatha; Shetty, J.; Prasad, K.; Tanvir Pasha, C.R. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol., 2014, 50(5), 498-505.
[http://dx.doi.org/10.1016/j.oraloncology.2013.11.008] [PMID: 24613543]
[26]
Kumar, A.; Chakravarty, N.; Bhatnagar, S.; Chowdhary, G.S. Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study. South Asian J. Cancer, 2019, 8(2), 108-111.
[http://dx.doi.org/10.4103/sajc.sajc_38_18] [PMID: 31069191]
[27]
Thai Hoa, N.T.; Quang Huy, H. Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Cureus, 2020, 12(5), e8105.
[http://dx.doi.org/10.7759/cureus.8105] [PMID: 32426197]
[28]
Rodríguez, M.O.; Rivero, T.C.; Del Castillo Bahi, R.; Muchuli, C.R.; Bilbao, M.A.; Vinageras, E.N.; Alert, J.; Galainena, J.J.; Rodríguez, E.; Gracia, E.; Mulén, B.; Wilkinson, B.; de Armas, E.L.; Pérez, K.; Pineda, I.; Frómeta, M.; Leonard, I.; Mullens, V.; Viada, C.; Luaces, P.; Torres, O.; Iznaga, N.; Crombet, T. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol. Ther., 2010, 9(5), 343-349.
[http://dx.doi.org/10.4161/cbt.9.5.10981] [PMID: 20448462]
[29]
Ramakrishnan, M.S.; Eswaraiah, A.; Crombet, T.; Piedra, P.; Saurez, G.; Iyer, H.; Arvind, A.S. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs, 2009, 1(1), 41-48.
[http://dx.doi.org/10.4161/mabs.1.1.7509] [PMID: 20046573]
[30]
Begg, CB; Mazumdar, M Operating Characteristics of a rank correlation test for publication bias., 1994, 50(4), 1088e101.
[http://dx.doi.org/10.2307/2533446]
[31]
Patil, V.M.; Noronha, V.; Joshi, A.; Agarwal, J.; Ghosh-Laskar, S.; Budrukkar, A.; Murthy, V.; Gupta, T.; Mahimkar, M.; Juvekar, S.; Arya, S.; Mahajan, A.; Agarwal, A.; Purandare, N.; Rangarajan, V.; Balaji, A.; Chaudhari, S.V.; Banavali, S.; Kannan, S.; Bhattacharjee, A.; D’Cruz, A.K.; Chaturvedi, P.; Pai, P.S.; Chaukar, D.; Pantvaidya, G.; Nair, D.; Nair, S.; Deshmukh, A.; Thiagarajan, S.; Mathrudev, V.; Manjrekar, A.; Dhumal, S.; Maske, K.; Bhelekar, A.S.; Nawale, K.; Chandrasekharan, A.; Pande, N.; Goel, A.; Talreja, V.; Simha, V.; Srinivas, S.; Swami, R.; Vallathol, D.H.; Dsouza, H.; Shrirangwar, S.; Turkar, S.; Abraham, G.; Thanky, A.H.; Patel, U.; Pandey, M.K.; Prabhash, K. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer, 2019, 125(18), 3184-3197.
[http://dx.doi.org/10.1002/cncr.32179] [PMID: 31150120]
[32]
Wainman, N.; Paul, N.; Brundage, M.; Pater, J.; Eisenhauer, E.; Koski, B.; Sadura, A.; Walsh, W. Common toxicity criteria: The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) experience. Controlled Clinical Trials., 1992, 13(5), 435.
[http://dx.doi.org/10.1016/0197-2456(92)90182-Y]
[33]
Yamaoka, T.; Kusumoto, S.; Ando, K.; Ohba, M.; Ohmori, T. Receptor tyrosine kinase-targeted cancer therapy. Int. J. Mol. Sci., 2018, 19(11), 3491.
[http://dx.doi.org/10.3390/ijms19113491] [PMID: 30404198]
[34]
Cohen, E.E.W. Role of epidermal growth factor receptor pathway- targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol., 2006, 24(17), 2659-2665.
[http://dx.doi.org/10.1200/JCO.2005.05.4577] [PMID: 16763280]
[35]
Ali, M.A.L.S.; Gunduz, M.; Nagatsuka, H.; Gunduz, E.; Cengiz, B.; Fukushima, K.; Beder, L.B.; Demircan, K.; Fujii, M.; Yamanaka, N.; Shimizu, K.; Grenman, R.; Nagai, N. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci., 2008, 99(8), 1589-1594.
[http://dx.doi.org/10.1111/j.1349-7006.2008.00861.x] [PMID: 18754871]
[36]
Xu, M.J.; Johnson, D.E.; Grandis, J.R. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev., 2017, 36(3), 463-473.
[http://dx.doi.org/10.1007/s10555-017-9687-8] [PMID: 28866730]
[37]
Loeffler-Ragg, J.; Schwentner, I.; Sprinzl, G.M.; Zwierzina, H. EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin. Investig. Drugs, 2008, 17(10), 1517-1531.
[http://dx.doi.org/10.1517/13543784.17.10.1517] [PMID: 18808311]
[38]
Mazorra, Z.; Chao, L.; Lavastida, A.; Sanchez, B.; Ramos, M.; Iznaga, N.; Crombet, T. Nimotuzumab: Beyond the EGFR signaling cascade inhibition. Semin. Oncol., 2018, 45(1-2), 18-26.
[http://dx.doi.org/10.1053/j.seminoncol.2018.04.008] [PMID: 30318080]
[39]
Bode, U.; Massimino, M.; Bach, F.; Zimmermann, M.; Khuhlaeva, E.; Westphal, M.; Fleischhack, G. Nimotuzumab treatment of malignant gliomas. Expert Opin. Biol. Ther., 2012, 12(12), 1649-1659.
[http://dx.doi.org/10.1517/14712598.2012.733367] [PMID: 23043252]
[40]
Cohen, R.B. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat. Rev., 2014, 40(4), 567-577.
[http://dx.doi.org/10.1016/j.ctrv.2013.10.002] [PMID: 24216225]
[41]
Yang, X.; Jia, X.C.; Corvalan, J.R.; Wang, P.; Davis, C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol., 2001, 38(1), 17-23.
[http://dx.doi.org/10.1016/S1040-8428(00)00134-7] [PMID: 11255078]
[42]
Song, Q; Li, X; Li, B Cetuximab in head and neck squamous cell carcinoma: A systematic review and meta-analysis Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi., 2015, 29(1), 67-75.
[43]
Talavera, A.; Friemann, R.; Gómez-Puerta, S.; Martinez-Fleites, C.; Garrido, G.; Rabasa, A.; López-Requena, A.; Pupo, A.; Johansen, R.F.; Sánchez, O.; Krengel, U.; Moreno, E. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res., 2009, 69(14), 5851-5859.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-4518] [PMID: 19584289]
[44]
Psyrri, A.; Fayette, J.; Harrington, K.; Gillison, M.; Ahn, M.J.; Takahashi, S.; Weiss, J.; Machiels, J.P.; Baxi, S.; Vasilyev, A.; Karpenko, A.; Dvorkin, M.; Hsieh, C.Y.; Thungappa, S.C.; Segura, P.P.; Vynnychenko, I.; Haddad, R.; Kasper, S.; Mauz, P.S.; Baker, V.; He, P.; Evans, B.; Wildsmith, S.; Olsson, R.F.; Yovine, A.; Kurland, J.F.; Morsli, N.; Seiwert, T.Y. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Ann. Oncol., 2023, 34(3), 262-274.
[http://dx.doi.org/10.1016/j.annonc.2022.12.008] [PMID: 36535565]
[45]
Harrington, K.J.; Burtness, B.; Greil, R.; Soulières, D.; Tahara, M.; de Castro, G., Jr; Psyrri, A.; Brana, I.; Basté, N.; Neupane, P.; Bratland, Å.; Fuereder, T.; Hughes, B.G.M.; Mesia, R.; Ngamphaiboon, N.; Rordorf, T.; Wan Ishak, W.Z.; Lin, J.; Gumuscu, B.; Swaby, R.F.; Rischin, D. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Updated results of the phase III KEYNOTE-048 study. J. Clin. Oncol., 2023, 41(4), 790-802.
[http://dx.doi.org/10.1200/JCO.21.02508] [PMID: 36219809]
[46]
Burtness, B.; Rischin, D.; Greil, R.; Soulières, D.; Tahara, M.; de Castro, G., Jr; Psyrri, A.; Brana, I.; Basté, N.; Neupane, P.; Bratland, Å.; Fuereder, T.; Hughes, B.G.M.; Mesia, R.; Ngamphaiboon, N.; Rordorf, T.; Wan Ishak, W.Z.; Ge, J.; Swaby, R.F.; Gumuscu, B.; Harrington, K. Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: Subgroup analysis by programmed death ligand-1 combined positive score. J. Clin. Oncol., 2022, 40(21), 2321-2332.
[http://dx.doi.org/10.1200/JCO.21.02198] [PMID: 35333599]
[47]
Lee, N.Y.; Ferris, R.L.; Psyrri, A.; Haddad, R.I.; Tahara, M.; Bourhis, J.; Harrington, K.; Chang, P.M.H.; Lin, J.C.; Razaq, M.A.; Teixeira, M.M.; Lövey, J.; Chamois, J.; Rueda, A.; Hu, C.; Dunn, L.A.; Dvorkin, M.V.; De Beukelaer, S.; Pavlov, D.; Thurm, H.; Cohen, E. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol., 2021, 22(4), 450-462.
[http://dx.doi.org/10.1016/S1470-2045(20)30737-3] [PMID: 33794205]
[48]
Girolami, I.; Pantanowitz, L.; Munari, E.; Martini, M.; Nocini, R.; Bisi, N.; Molteni, G.; Marchioni, D.; Ghimenton, C.; Brunelli, M.; Eccher, A. Prevalence of PD-L1 expression in head and neck squamous precancerous lesions: A systematic review and meta-analysis. Head Neck, 2020, 42(10), 3018-3030.
[http://dx.doi.org/10.1002/hed.26339] [PMID: 32567746]
[49]
Girolami, I.; Marletta, S.; Fiorentino, V.; Battocchio, S.; Cerbelli, B.; Fiamengo, B.; Gerosa, C.; Gianatti, A.; Morelli, L.; Riva, G.; Zagami, M.G.; Fusco, N.; Munari, E.; L’Imperio, V.; Pagni, F.; Morbini, P.; Martini, M.; Eccher, A. Effect of radio-chemotherapy on PD-L1 immunohistochemical expression in head and neck squamous cell carcinoma. J. Pers. Med., 2023, 13(2), 363.
[http://dx.doi.org/10.3390/jpm13020363] [PMID: 36836595]
[50]
Marletta, S.; Fusco, N.; Munari, E.; Luchini, C.; Cimadamore, A.; Brunelli, M.; Querzoli, G.; Martini, M.; Vigliar, E.; Colombari, R.; Girolami, I.; Pagni, F.; Eccher, A. Atlas of PD-L1 for pathologists: Indications, scores, diagnostic platforms and reporting systems. J. Pers. Med., 2022, 12(7), 1073.
[http://dx.doi.org/10.3390/jpm12071073] [PMID: 35887569]
[51]
Paolino, G.; Pantanowitz, L.; Barresi, V.; Pagni, F.; Munari, E.; Moretta, L.; Brunelli, M.; Bariani, E.; Vigliar, E.; Pisapia, P.; Malapelle, U.; Troncone, G.; Girolami, I.; Eccher, A. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. Pathol. Res. Pract., 2021, 226, 153605.
[http://dx.doi.org/10.1016/j.prp.2021.153605] [PMID: 34530257]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy